

Total artificial heart

Clinical Policy ID: CCP.1250

Recent review date: 9/2023

Next review date: 1/2024

Policy contains: Heart failure; mechanical circulatory support; total artificial heart.

AmeriHealth Caritas Ohio has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Ohio's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by AmeriHealth Caritas Ohio when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Ohio's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Ohio's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Ohio will update its clinical policies as necessary. AmeriHealth Caritas Ohio's clinical policies are not guarantees of payment.

Coverage policy

The SynCardia Temporary Cardio West Total Artificial Heart (TAH-t; SynCardia Systems, LLC, Tucson, Arizona) is clinically proven and, therefore, may be medically necessary as a bridge to transplantation when implantation is performed at a Medicare-approved heart transplantation facility or at a facility with a United Network for Organ Sharing-approved heart transplantation program for members who meet all of the following criteria (Feldman 2013; Peura, 2012; Ponikowski, 2016):

- Candidate for heart transplantation or is undergoing evaluation to determine candidacy for heart transplantation.
- Biventricular failure.
- Not expected to survive until a donor heart can be obtained.
- No other surgical or medical treatment options.
- Ineligible for univentricular or biventricular support devices.
- Receiving maximal medical therapy including intravenous inotropic support.

The Abiomed® Implantable Replacement Heart (Abiomed, Inc., Danvers, Massachusetts) is clinically proven and, therefore, medically necessary as destination therapy under a Humanitarian Device Exemption for members who meet all of the following criteria (U.S. Food and Drug Administration, 2006):

- Not a candidate for heart transplantation.
- Not treatable by left ventricular assist device destination therapy.
- Not weanable from biventricular support if on such support.
- Severe biventricular end stage heart disease.

- Less than 75 years of age.
- Require multiple inotropic support.

Limitations

All other uses of the total artificial heart are not medically necessary.

Absolute contraindications to the total artificial heart include conditions that would generally exclude patients for heart transplantation, including, but not limited to (Peura, 2012; Yancy, 2013):

- Chronic irreversible hepatic or respiratory failure.
- Irreversible kidney failure unless bridge to heart–kidney transplantation is considered.
- Active systemic infection or prolonged intubation.
- Coagulation disorders.
- Irreversible kidney failure unless bridge to heart–kidney transplantation is considered.
- Insufficient space in the thorax and/or abdominal cavity for the device.
- Structural heart disease that prohibits or may interfere with a successful implantation (e.g., uncorrected valvular disease).
- Underlying coagulopathy, either an international normalized ratio < 2.5 or a platelet count $< 50,000$. A contraindication to anticoagulation is a contraindication to mechanical circulatory support in most situations.

Relative contraindications to the total artificial heart include, but are not limited to (Peura, 2012; Ponikowski, 2016):

- Age > 75 years for destination therapy.
- Obesity $> 40 \text{ kg/m}^2$ or malnutrition.
- Musculoskeletal disease that impairs rehabilitation.
- Untreated malignancy.
- Severe peripheral vascular disease.
- Active substance abuse.
- Impaired cognitive function.
- Unmanaged psychiatric disorder.
- Inadequate psychosocial support.

Alternative covered services:

- Cardiac rehabilitation.
- Cardiac resynchronization (implantable cardioverter-defibrillator; cardiac resynchronization therapy).
- Continuous intravenous inotropic infusion.
- Corrective surgery (e.g., coronary artery bypass or valve replacement).
- Extracorporeal membrane oxygenation.
- Heart transplantation.
- Intra-aortic balloon pump.
- Percutaneous coronary intervention.
- Pharmacologic therapy, including but not limited to: angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers (or inhibitors); angiotensin-receptor neprilysin inhibitors; I_f channel blocker (or inhibitor); beta blockers; aldosterone antagonists; hydralazine and isosorbide dinitrate (specifically benefits African Americans with heart failure); diuretics; digoxin; statins; and anticoagulants.

Background

Heart failure is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood that fails to meet the body's needs (Yancy, 2013). Disorders of the pericardium, myocardium, endocardium, heart valves, great vessels, or certain metabolic abnormalities can cause heart failure and lead to episodes of arrhythmia, increasing pump failure, and premature death. Dyspnea and fatigue are the principal symptoms of heart failure; infants may also present with poor feeding, poor growth, excessive sweating, or even low blood pressure.

The class and type of heart failure are important considerations for managing patients with heart failure (American Heart Association, 2023). Most patients with heart failure have symptoms due to left ventricular impairment. Several validated classification systems are available to grade the severity of heart failure, including: the four-stage New York Heart Association functional classification; the American College of Cardiology/American Heart Association staging system (Hunt, 2009); the European Society of Cardiology (Ponikowski, 2016) system; and the Ross Classification System for infants and younger children (Rosenthal, 2004). The Interagency Registry for Mechanically Assisted Circulatory Support (2020), which acquires data on patients supported with U.S. Food and Drug Administration-approved mechanical circulatory support devices, further stratifies patients with advanced heart failure into seven clinical profiles by their signs and symptoms (See Appendix).

A subset of patients with chronic heart failure will continue to progress and develop persistently severe symptoms despite maximum guideline-directed medical therapy. Patients with advanced heart failure typically have symptoms at rest or with minimal exertion and cannot perform many activities of daily living. They are usually classified as American College of Cardiology/American Heart Association stage D or New York Heart Association Class IV and have clinically significant circulatory compromise (see Appendix).

Advanced heart failure is a debilitating condition for which heart transplantation offers the best treatment option. However, the supply of donor hearts is diminishing, and demand greatly exceeds supply. The shortage of donor hearts has encouraged the development of artificial mechanical devices that can assist or replace the function of the failing heart. A ventricular assist device is an electromechanical pump attached to the native heart and vessels to augment cardiac output. It is designed to partially or completely assist the ventricles of the native heart.

A total artificial heart is attached to the pulmonary artery and aorta; it is designed to completely replace cardiac function and generally requires the removal of the patient's heart. The U.S. Food and Drug Administration (2006, 2023) has approved two total artificial hearts for marketing in the United States: the SynCardia Temporary Cardio West total artificial heart and the Abiocr Implantable Replacement Heart.

The Abiocr Implantable Replacement Heart was approved as a Humanitarian Use Device within the Humanitarian Device Exemption regulatory pathway as destination therapy designated for patients with rare diseases or conditions that affect or are manifested in not more than 8,000 individuals in the United States per year. This pathway exempts the Abiocr from the effectiveness requirements of other regulatory pathways and subjects the device to certain profit and use restrictions.

The SynCardia 70cc model with a Circulatory Support System console (external pneumatic driver) received government approval as a bridge to transplant in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure. The device was indicated for patients with body surface areas of at least 1.7 m² for inpatient use only. In 2012, the U.S. Food and Drug Administration approved a smaller Companion 2 (C2) Driver system for hospital use conditioned on a post-approval surveillance study to assess post-market performance. The final analysis indicated a higher mortality rate and higher stroke rate for patients initially supported with the SynCardia C2 Driver System compared to patients supported with the initial generation driver (Hicks, 2018). The

Administration recommended that practitioners carefully consider these results when making treatment decisions, discuss the risks and benefits of the C2 Driver System with patients, and voluntarily report any adverse events or suspected adverse events.

In 2014, the SynCardia Freedom® Portable Driver was approved for use at home. Both drivers facilitate recovery by allowing ambulation, aggressive physiotherapy, and eventual hospital discharge (Noly, 2020). In March of 2020, the U.S. Food and Drug Administration approved a smaller SynCardia model called the 50cc temporary Total Artificial Heart suitable for smaller statured adults and pediatric patients.

As of mid-2022, the SynCardia total artificial heart has been implanted in over 2,000 patients worldwide (Henn, 2022). The number of total artificial heart procedures is increasing. In the U.S., procedures rose from 9 to 63 from 2004-2006 to 2009-2011, according to a 20% national sample (Pasha, 2022).

Findings

A guideline from the American Association for Thoracic Surgery and International Society for Heart and Lung Transplant states that total artificial heart as initial management can benefit patients with advanced right ventricular failure (Kirklin, 2020).

A guideline from the European Society of Cardiology supports mechanical circulatory support, including total artificial heart, as a bridge to transplant for patient with advanced heart failure alive at high risk of death before transplant prior to organ donation (McDonagh, 2021).

A guideline from the United Kingdom states that total artificial heart implant for end-stage biventricular should only be used with special arrangements, consent, or research, due to limited evidence of effectiveness (National Institute for Health and Care Excellence, 2017).

Few randomized comparative studies are available to guide patient or device selection for the patient requiring mechanical circulatory support beyond criteria established for U.S. Food and Drug Administration approval. In adult populations, some generalizations from consensus-based guidelines can be made:

- As bridge to transplantation, total artificial hearts are available for patients with biventricular heart failure who meet criteria for heart transplantation and are at risk of imminent death. The effectiveness of temporary total artificial heart has been established only in patients with idiopathic and ischemic cardiomyopathies in a hospital setting (Ponikowski, 2016).
- The safety and efficacy of the total artificial heart as destination therapy or when used with a portable driver outside the hospital setting have not been established (Peura, 2012). Patient selection is based on enrollment criteria in pivotal randomized controlled trials used to support U.S. Food and Drug Administration approval. Studies have not validated other preoperative variables to further refine patient selection and thereby improve patient outcomes.

In 2018, the policy ID was changed from CP# 04.02.07 to CCP.1250.

In 2019, we removed ventricular assist devices from the policy. The coverage policy will focus solely on the total artificial heart, for which we identified no new information to add.

In 2020, we removed references and text that addressed only ventricular assist devices. We added patient outcome data from an Interagency Registry for Mechanically Assisted Circulatory Support study inclusive of 450 patients who received a total artificial heart between June 2006 and April 2017 (Arabía, 2018). Most patients were Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 (43%) or 2 (37%) at implantation representing severe, rapidly declining dilated cardiomyopathy and ischemic cardiomyopathy. Two

hundred sixty-six patients underwent transplantation, and 162 died. Overall 3-, 6-, and 12-month actuarial survival rates were 73%, 62%, and 53%, respectively. Risk factors for death included older age ($P = .001$), need for pre-implantation dialysis ($P = .006$), higher creatinine ($P = .008$) and lower albumin ($P < .001$) levels, and implantation at a low-volume center (defined as ≤ 10 total artificial heart procedures during study period; $P < .001$). Experienced centers have better outcomes, likely related to patient selection, timing of implantation, patient care, and device management.

We included a systematic review and meta-analysis of 12 studies comparing the SynCardia total artificial heart to the HeartWare™ HVAD™ system (Medtronic, Minneapolis, Minnesota) used off-label as biventricular support for management of biventricular heart failure (Maynes, 2020). The results from 512 recipients in the SynCardia group and 38 recipients in the HeartWare group were pooled for meta-analysis. The groups were statistically comparable at baseline. There were no statistically significant differences between the groups with respect to post-operative bleeding ($P = .22$) and overall mortality at 120 days ($P = .44$). SynCardia recipients had a shorter duration of support (mean = 71 days, 95% confidence interval, 15 days to 127 days versus 167 days, 95% confidence interval 116 days to 217 days, $P = .01$). However, HeartWare recipients were more likely to be discharged home on support (73% versus 6% $P < .01$).

We added information on the Abiomed total artificial heart to the coverage section, as it is approved for use as destination therapy under a Humanitarian Device Exemption (U.S. Food and Drug Administration, 2006).

In 2021, we identified no newly published literature to add to the policy.

In 2022, we added several new large reviews, which reported:

- SynCardia had been implanted in over 2,000 patients; overall one-year survival in patients supported by the device is 42%, and 83% for those who make it to transplant (Henn, 2022).
- Of all 471 total artificial heart implants in the United States from 2015-2018, mortality one year after transplant was 20.0%. Centers that performed fewer than 10 implants were linked with significantly higher mortality on the total artificial heart ($P < .001$) and post-transplant ($P = .039$) (Itagaki, 2022).
- Of 433 patients who underwent total artificial heart with SynCardia as a bridge to transplantation, one-year mortality was 20%. The mortality among those on a wait list was 7.4% (Coyan, 2022).

In 2023, we added several reviews:

- A review of 100 recipients of SynCardia implants tracked for a median of 4.6 years showed 61 were successfully bridged to transplantation and 39 died on total artificial heart support. Over half (20 of 39) of the deaths were caused by multisystem organ failure. Survival after transplantation at six months, one year, and five years were 95.1%, 86.6%, and 77.5% (Malas, 2023).
- A review of 75 inpatient total artificial heart patients (U.S.) showed all but one was 70 years or younger. The death rate was 29.3%, and the most common complications were acute renal failure (69.3%) and infections (28.0%) (Pasha, 2022).
- Outcomes for heart transplant patients with a total artificial heart as a bridge to transplantation ($n = 392$) from 2005-2020 were compared with those with durable left ventricular assist device and de novo heart transplants. The total artificial heart group had higher dialysis dependence ($P < .001$); lower 10-year survival ($P = .04$); but similar 10-year survival conditional on one-year survival ($P > .20$) (Chen, 2022).

References

On June 22, 2023, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “Heart-assist devices” (MeSH), “Heart, artificial”

(MeSH), “SynCardia,” “Abiocor,” and “total artificial heart.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

American Heart Association. What is heart failure? <https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure>. Last reviewed March 22, 2023.

Arabía FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. *J Heart Lung Transplant*. 2018;37(11):1304-1312. Doi: 10.1016/j.healun.2018.04.004.

Chen Q, Chan J, Askmerov A, et al. Heart transplantation after total artificial heart bridging – outcomes over 15 years. *Clin Transplant*. 2022;36(11):e14781. Doi: 10.1111/ctr.14781.

Coyan GN, Huckaby LV, Diaz-Castrillon CE, Miguelino AM, Kilic A. Trends and outcomes following total artificial heart as bridge to transplant from the UNOS database. *Card Surg*. 2022;37(5):1215-1221.

Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: Executive summary. *J Heart Lung Transplant*. 2013;32(2):157-187. Doi: 10.1016/j.healun.2012.09.013.

Henn MC, Mokadam NA. Total artificial heart as a bridge to transplantation. *Curr Opin Organ Transplant*. 2022;27(3):222-228. Doi: 10.1097/MOT.0000000000000982.

Hicks L. FDA Warns of Death, Stroke Due to Power System Problems with Total Artificial Heart System. <https://www.tctmd.com/news/fda-warns-deaths-stroke-due-power-system-problems-total-artificial-heart-system>. Published August 17, 2018.

Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the American College of Cardiology/American Heart Association 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. *J Am Coll Cardiol*. 2009;53(15):e1-e90. Doi: 10.1016/j.jacc.2008.11.013.

Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Home page. University of Alabama Birmingham website. <https://biolincc.nhlbi.nih.gov/studies/intermacs/#:~:text=The%20Interagency%20Registry%20for%20Mechanically,due%20to%20advanced%20heart%20failure>. Last updated January 21, 2020.

Itagaki S, Toyoda N, Egorova N, et al. Total artificial heart implantation as a bridge to transplantation in the United States. *J Thorac Cardiovasc Surg*. 2022;S0022-5223(22)00385-3.

Kirklin JK, Pagani FD, Goldstein DJ, et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. *J Thorac Cardiovasc Surg*. 2020;159(3):865-896. Doi: 10.1016/j.jtcvs.2019.12.021.

Malas J, Chen Q, Akhmerov A, et al. Experience with SynCardia total artificial heart as a bridge to transplantation in 100 patients. *Ann Thorac Surg*. 2023;115(3):725-732. Doi: 10.1016/j.athoracsur.2022.11.034.

Maynes EJ, O'Malley TJ, Luc JGY, et al. Comparison of SynCardia total artificial heart and HeartWare HVAD biventricular support for management of biventricular heart failure: A systematic review and meta-analysis. *Ann Cardiothorac Surg*. 2020;9(2):69-80. Doi: 10.21037/acs.2020.03.07.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association of the ESC. *Eur J Heart Fail*. 2022;24(1):4-131. Doi: 10.1002/ejhf.2333.

National Institute for Health and Care Excellence. Interventional procedure overview of artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure [IPG602]. <https://www.nice.org.uk/guidance/ipg602/evidence/overview-final-pdf-4718098333>. Published June 2017.

Noly PE, Ben Ali W, Lamarche Y, Carrier M. Status, indications, and use of cardiac replacement therapy in the era of multimodal mechanical approaches to circulatory support: A scoping review. *Can J Cardiol*. 2020;36(2):261-269. Doi: 10.1016/j.cjca.2019.11.027.

Pasha AK, Lee JZ, Desai H, Hashemzadeh M, Movahed MR. In-hospital complications associated with total artificial heart implantation in the United States between 2004 to 2011. *Am J Cardiovasc Dis*. 2022;12(5):278-282. <https://pubmed.ncbi.nlm.nih.gov/36419860/>.

Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: A scientific statement from the American Heart Association. *Circulation*. 2012;126(22):2648-2667. Doi: 10.1161/CIR.0b013e3182769a54.

Ponikowski P, Voors AA, Anker SD, et al. 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (European Society of Cardiology). Developed with the special contribution of the Heart Failure Association (HFA) of the European Society of Cardiology. *Eur J Heart Fail*. 2016;18(8):891-975. Doi: 10.1002/ejhf.592.

Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. *J Heart Lung Transplant*. 2004; 23(12):1313-1333.

The Criteria Committee of the New York Heart Association. *Nomenclature and criteria for diagnosis of diseases of the heart and great vessels* 9th ed. Boston, MA: Little & Brown; 1994. <https://www.worldcat.org/title/nomenclature-and-criteria-for-diagnosis-of-diseases-of-the-heart-and-great-vessels/oclc/29430883>.

U.S. Food and Drug Administration. AbioCor Implantable Replacement Heart. Humanitarian device exemption approval letter [H040006]. https://www.accessdata.fda.gov/cdrh_docs/pdf4/H040006A.pdf. Published September 5, 2006.

U.S. Food and Drug Administration. Premarket Approval (PMA) database search using product code LOZ. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm>. Last updated June 19, 2023.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. Doi: 10.1016/j.jacc.2013.05.019.

Policy updates

7/2016: initial review date and clinical policy effective date: 10/2016

10/2017: Policy references updated.

8/2018: Policy references updated. Policy ID changed.

9/2019: Policy references updated. Ventricular assist devices removed from policy. Focus on total artificial hearts only.

9/2020: Policy references updated. Abiocr coverage added.

9/2021: Policy references updated.

9/2022: Policy references updated.

9/2023: Policy references updated.

Appendix

New York Heart Association Functional Classification of Heart Failure:

- Class I. No symptoms and no limitation in ordinary physical activity, e.g., shortness of breath when walking, climbing stairs etc.
- Class II. Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
- Class III. Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (~ up to 300 feet). Comfortable only at rest.
- Class IV. Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

American College of Cardiology Foundation/American Heart Association Stages of Heart Failure (Hunt, 2009):

- Stage 1. At high risk for heart failure but without structural heart disease or symptoms of heart failure.
- Stage 2. Structural heart disease but without signs or symptoms of heart failure.
- Stage 3. Structural heart disease with prior or current symptoms of heart failure.
- Stage 4. Refractory heart failure requiring specialized interventions. Unable to carry on any physical activity without symptoms of heart failure, or symptoms of heart failure at rest.

Interagency Registry for Mechanically Assisted Circulatory Support profiles for classifying patients with advanced heart failure at time of implant (2018):

- Profile 1. Critical cardiogenic shock, “crash and burn.”
- Profile 2. Progressive decline, on inotropic support or in whom inotropic infusions cannot be maintained due to tachyarrhythmias, clinical ischemia or other intolerance.
- Profile 3. Stable but inotrope dependent, or has a temporary circulatory support device after repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive organ dysfunction (usually renal).
- Profile 4. Resting symptoms describes a patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of daily living.
- Profile 5. Exertion intolerant living predominantly within the house or housebound.
- Profile 6. Exertion limited, comfortable at rest without evidence of fluid overload and able to do some mild activity but easily fatigued with any meaningful physical exertion, and likely to have had a hospitalization for heart failure within the past year.
- Profile 7. Advanced New York Heart Association Class III, clinically stable with a reasonable level of comfortable activity, despite history of previous decompensation that is not recent.

Source: New York Heart Association, 1994